|
|
|
|
|
|
Early, Late, PrEP, PEP |
Covid Analysis (Preprint) (meta analysis) |
meta-analysis |
Famotidine for COVID-19: real-time meta analysis of 23 studies |
Details
• Statistically significant improvements are seen for mortality, hospitalization, and recovery. 12 studies from 12 independent teams in 5 different countries show statistically significant improvements in isolation (8 for the most serious.. |
|
Details
Source
PDF
Early, Late, PrEP, PEP
Early, Late, PrEP, PEP
|
Famotidine for COVID-19: real-time meta analysis of 23 studies |
Covid Analysis (Preprint) (meta analysis) |
• Statistically significant improvements are seen for mortality, hospitalization, and recovery. 12 studies from 12 independent teams in 5 different countries show statistically significant improvements in isolation (8 for the most serious outcome).• Meta analysis using the most serious outcome reported shows 15% [4‑25%] improvement. Results are better for Randomized Controlled Trials, similar after exclusions, and similar for peer-reviewed studies. Early treatment is more effective than late treatment. • In exclusion sensitivity analysis, statistical significance is lost after excluding only one of 23 studies in pooled analysis.• While many treatments have some level of efficacy, they do not replace vaccines and other measures to avoid infection. None of the famotidine studies show zero events in the treatment arm. Multiple treatments are typically used in combination, and other treatments are significantly more effective.• No treatment, vaccine, or intervention is 100% available and effective for all variants. All practical, effective, and safe means should be used. Denying the efficacy of treatments increases mortality, morbidity, collateral damage, and endemic risk.• All data to reproduce this paper and sources are in the appendix.
Covid Analysis et al., 6/27/2022, preprint, 1 author.
|
Submit Corrections or Comments
|
|
Late |
Zangeneh et al., Obesity Medicine, doi:10.1016/j.obmed.2022.100420 |
death, ↓39.0%, p=0.01 |
Survival analysis based on body mass index in patients with Covid-19 admitted to the intensive care unit of Amir Al-Momenin Hospital in Arak – 2021 |
Details
Retrospective 193 ICU patients in Iran, showing lower mortality with famotidine treatment. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
Survival analysis based on body mass index in patients with Covid-19 admitted to the intensive care unit of Amir Al-Momenin Hospital in Arak – 2021 |
Zangeneh et al., Obesity Medicine, doi:10.1016/j.obmed.2022.100420 |
Retrospective 193 ICU patients in Iran, showing lower mortality with famotidine treatment.
risk of death, 39.0% lower, HR 0.61, p = 0.01, Cox proportional hazards.
|
Zangeneh et al., 5/13/2022, retrospective, Iran, Middle East, peer-reviewed, 3 authors.
|
Submit Corrections or Comments
|
|
PrEPPEP |
MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 |
cases, ↓7.0%, p=0.16 |
Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications |
Details
Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing no significant differences in cases with chronic use of famotidine. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications |
MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 |
Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing no significant differences in cases with chronic use of famotidine.
risk of case, 7.0% lower, OR 0.93, p = 0.16, RR approximated with OR.
|
MacFadden et al., 3/29/2022, retrospective, Canada, North America, peer-reviewed, 9 authors, study period 15 January, 2020 - 31 December, 2020.
|
Submit Corrections or Comments
|
|
Late |
Siraj et al., Indian Journal of Clinical Practice, 32:9 |
death, ↓36.2%, p=0.002 |
Efficacy of Various Treatment Modalities on Patient-related Outcome in Hospitalized COVID-19 Patients – A Retrospective Study |
Details
Retrospective 1,000 COVID+ hospitalized patients in India, showing lower mortality with famotidine and remdesivir in multivariable logistic regression. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
Efficacy of Various Treatment Modalities on Patient-related Outcome in Hospitalized COVID-19 Patients – A Retrospective Study |
Siraj et al., Indian Journal of Clinical Practice, 32:9 |
Retrospective 1,000 COVID+ hospitalized patients in India, showing lower mortality with famotidine and remdesivir in multivariable logistic regression.
risk of death, 36.2% lower, RR 0.64, p = 0.002, treatment 183 of 711 (25.7%), control 122 of 289 (42.2%), NNT 6.1, adjusted, OR converted to RR, multivariable.
|
Siraj et al., 2/28/2022, retrospective, India, South Asia, peer-reviewed, median age 56.0, 13 authors, study period March 2020 - December 2020.
|
Submit Corrections or Comments
|
|
Review |
Kory et al., Journal of Clinical Medicine Research, doi:10.14740/jocmr4658 (Review) |
review |
“MATH+” Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale |
Details
Review of the data supporting the MATH+ hospital treatment protocol for COVID-19. |
|
Details
Source
PDF
Review
Review
|
“MATH+” Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale |
Kory et al., Journal of Clinical Medicine Research, doi:10.14740/jocmr4658 (Review) |
Review of the data supporting the MATH+ hospital treatment protocol for COVID-19.
Kory et al., 2/24/2022, peer-reviewed, 6 authors.
|
Submit Corrections or Comments
|
|
Late |
Pahwani et al., Cureus, doi:10.7759/cureus.22404 |
death, ↓11.1%, p=1.00 |
Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 |
Details
RCT with 89 famotidine and 89 control patients in Pakistan, showing faster recovery but no significant difference in mortality. 40mg oral famotidine daily. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 |
Pahwani et al., Cureus, doi:10.7759/cureus.22404 |
RCT with 89 famotidine and 89 control patients in Pakistan, showing faster recovery but no significant difference in mortality. 40mg oral famotidine daily.
risk of death, 11.1% lower, RR 0.89, p = 1.00, treatment 8 of 89 (9.0%), control 9 of 89 (10.1%), NNT 89.
|
risk of mechanical ventilation, 12.5% lower, RR 0.88, p = 0.73, treatment 21 of 89 (23.6%), control 24 of 89 (27.0%), NNT 30.
|
risk of ICU admission, 10.0% lower, RR 0.90, p = 0.86, treatment 18 of 89 (20.2%), control 20 of 89 (22.5%), NNT 44.
|
hospitalization time, 16.5% lower, relative time 0.83, p < 0.001, treatment mean 8.6 (±1.6) n=89, control mean 10.3 (±2.2) n=89.
|
recovery time, 9.6% lower, relative time 0.90, p = 0.001, treatment mean 8.5 (±1.7) n=89, control mean 9.4 (±1.9) n=89.
|
Pahwani et al., 2/20/2022, Randomized Controlled Trial, Pakistan, South Asia, peer-reviewed, mean age 52.0, 8 authors, study period December 2020 - September 2021.
|
Submit Corrections or Comments
|
|
Early |
Brennan et al., Gut, doi:10.1136/gutjnl-2022-326952 |
no recov., ↓48.1%, p=0.23 |
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial |
Details
Small RCT with 27 famotidine and 28 placebo patients, showing improved recovery with treatment. Recovery was faster with treatment for 14 of 16 symptoms. There was no mortality or hospitalization. NCT04724720. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial |
Brennan et al., Gut, doi:10.1136/gutjnl-2022-326952 |
Small RCT with 27 famotidine and 28 placebo patients, showing improved recovery with treatment. Recovery was faster with treatment for 14 of 16 symptoms. There was no mortality or hospitalization. NCT04724720.
risk of no recovery, 48.1% lower, RR 0.52, p = 0.23, treatment 5 of 27 (18.5%), control 10 of 28 (35.7%), NNT 5.8, day 28, ITT.
|
risk of no recovery, 43.2% lower, RR 0.57, p = 0.34, treatment 4 of 19 (21.1%), control 10 of 27 (37.0%), NNT 6.3, day 28, PP.
|
estimated time to 50% resolution, 28.1% lower, relative time 0.72, p < 0.01, treatment 27, control 28.
|
Brennan et al., 2/10/2022, Double Blind Randomized Controlled Trial, USA, North America, peer-reviewed, 31 authors, study period January 2021 - April 2021, average treatment delay 4.0 days, trial NCT04724720.
|
Submit Corrections or Comments
|
|
PrEPPEP |
Park et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00549-7 |
Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study |
Details
Retrospective 62,117 histamine-2 receptor antagonist users in South Korea, showing lower risk of COVID-19 with histamine-2 receptor antagonist use (famotidine, ranitidine, nizatidine, lafutidine, and cimetidine), without statistical signi.. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study |
Park et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00549-7 |
Retrospective 62,117 histamine-2 receptor antagonist users in South Korea, showing lower risk of COVID-19 with histamine-2 receptor antagonist use (famotidine, ranitidine, nizatidine, lafutidine, and cimetidine), without statistical significance (RR 0.48 [0.17–1.37] with 1:4 PSM).
Park et al., 1/17/2022, retrospective, South Korea, Asia, peer-reviewed, 7 authors, study period 1 January, 2020 - 15 May, 2020.
|
Submit Corrections or Comments
|
|
PrEPPEP |
Wallace et al., BMJ Open, doi:10.1136/bmjopen-2021-050051 |
death, ↑11.0%, p=0.33 |
Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study |
Details
Retrospective 9,532 hospitalized COVID+ veterans in the USA, showing no significant difference in mortality with famotidine use. The study provides results for use before, after, and before+after. Before+after should more accurately repre.. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study |
Wallace et al., BMJ Open, doi:10.1136/bmjopen-2021-050051 |
Retrospective 9,532 hospitalized COVID+ veterans in the USA, showing no significant difference in mortality with famotidine use. The study provides results for use before, after, and before+after. Before+after should more accurately represent prophylaxis up to COVID-19 infection (and continued use). Before included use up to 2 years before, and after included use up to 60 days later.
risk of death, 11.0% higher, RR 1.11, p = 0.33, treatment 98 of 423 (23.2%), control 1,436 of 7,521 (19.1%), adjusted, OR converted to RR, multivariable.
|
Wallace et al., 12/31/2021, retrospective, database analysis, USA, North America, peer-reviewed, 6 authors.
|
Submit Corrections or Comments
|
|
Late |
Wagner et al., American Journal of Gastroenterology, doi:10.14309/01.ajg.0000779364.64867.ec |
death, ↓70.0%, p<0.0001 |
Famotidine versus Pantoprazole Use and Clinical Outcomes in Patients Hospitalized With COVID-19: A Retrospective Study |
Details
Retrospective 2,184 hospitalized patients in the USA, 638 treated with famotidine, showing lower mortality with treatment. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
Famotidine versus Pantoprazole Use and Clinical Outcomes in Patients Hospitalized With COVID-19: A Retrospective Study |
Wagner et al., American Journal of Gastroenterology, doi:10.14309/01.ajg.0000779364.64867.ec |
Retrospective 2,184 hospitalized patients in the USA, 638 treated with famotidine, showing lower mortality with treatment.
risk of death, 70.0% lower, OR 0.30, p < 0.001, treatment 638, control 819, adjusted, multivariable, RR approximated with OR.
|
Wagner et al., 10/31/2021, retrospective, USA, North America, peer-reviewed, 5 authors, study period March 2020 - March 2021.
|
Submit Corrections or Comments
|
|
Late |
Stolow et al., American Journal of Gastroenterology, doi:10.14309/01.ajg.0000778736.01714.cd |
death, ↑518.9%, p<0.001 |
A Retrospective Review: Famotidine Use Is Not Associated With Improved Outcomes in Hospitalized Patients With COVID-19 |
Details
Retrospective 489 COVID+ hospitalized patients in the USA, showing higher mortality with famotidine treatment. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
A Retrospective Review: Famotidine Use Is Not Associated With Improved Outcomes in Hospitalized Patients With COVID-19 |
Stolow et al., American Journal of Gastroenterology, doi:10.14309/01.ajg.0000778736.01714.cd |
Retrospective 489 COVID+ hospitalized patients in the USA, showing higher mortality with famotidine treatment.
risk of death, 518.9% higher, OR 6.19, p < 0.001, treatment 137, control 352, RR approximated with OR.
|
risk of ICU admission, 2389.6% higher, OR 24.90, p < 0.001, treatment 137, control 352, RR approximated with OR.
|
Stolow et al., 10/31/2021, retrospective, USA, North America, peer-reviewed, 9 authors.
|
Submit Corrections or Comments
|
|
PrEPPEP |
Razjouyan et al., Nicotine & Tobacco Research, doi:10.1093/ntr/ntab223 |
death, ↓27.0%, p=0.006 |
Smoking Status and Factors associated with COVID-19 In-Hospital Mortality among US Veterans |
Details
Retrospective 10,074 veterens in the USA, showing lower mortality with existing famotidine use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
Smoking Status and Factors associated with COVID-19 In-Hospital Mortality among US Veterans |
Razjouyan et al., Nicotine & Tobacco Research, doi:10.1093/ntr/ntab223 |
Retrospective 10,074 veterens in the USA, showing lower mortality with existing famotidine use.
risk of death, 27.0% lower, OR 0.73, p = 0.006, treatment 93, control 9,981, adjusted, RR approximated with OR.
|
Razjouyan et al., 10/25/2021, retrospective, USA, North America, peer-reviewed, 7 authors.
|
Submit Corrections or Comments
|
|
Late |
Kuno et al., Journal of Medical Virology, doi:10.1002/jmv.27375 |
death, 0.0%, p=0.97 |
The association between famotidine and in‐hospital mortality of patients with COVID‐19 |
Details
PSM retrospective 9,565 COVID-19 hospitalized patients in the USA, 1,593 receiving famotidine, showing no significant difference in mortality. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
The association between famotidine and in‐hospital mortality of patients with COVID‐19 |
Kuno et al., Journal of Medical Virology, doi:10.1002/jmv.27375 |
PSM retrospective 9,565 COVID-19 hospitalized patients in the USA, 1,593 receiving famotidine, showing no significant difference in mortality.
risk of death, no change, OR 1.00, p = 0.97, treatment 1,593, control 7,972, RR approximated with OR.
|
Kuno et al., 10/11/2021, retrospective, propensity score matching, USA, North America, peer-reviewed, 4 authors, study period 1 March, 2020 - 30 March, 2021.
|
Submit Corrections or Comments
|
|
PrEPPEP |
Fung et al., PLoS ONE, doi:10.1371/journal.pone.0266922 (preprint 10/1/2021) |
death, 0.0%, p=1.00 |
Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients |
Details
Retrospective database analysis of 374,229 patients in the USA, showing higher cases, lower hospitalizations, and no change in mortality with famotidine use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients |
Fung et al., PLoS ONE, doi:10.1371/journal.pone.0266922 (preprint 10/1/2021) |
Retrospective database analysis of 374,229 patients in the USA, showing higher cases, lower hospitalizations, and no change in mortality with famotidine use.
risk of death, no change, HR 1.00, p = 1.00, vs. never used.
|
risk of hospitalization, 6.0% lower, HR 0.94, p < 0.001, vs. never used.
|
risk of case, 12.0% higher, HR 1.12, p < 0.001, vs. never used.
|
Excluded in after exclusion results of meta analysis:
not fully adjusting for the different baseline risk of systemic autoimmune patients.
Fung et al., 10/1/2021, retrospective, population-based cohort, USA, North America, peer-reviewed, 6 authors.
|
Submit Corrections or Comments
|
|
Late |
Taşdemir et al., Konuralp Tıp Dergisi, doi:10.18521/ktd.935888 |
death, ↓44.7%, p=0.29 |
Famotidine in COVID-19 treatment |
Details
Retrospective 179 hospitalized patients in Turkey, 85 treated with famotidine and 94 treated with pantoprazole, showing faster recovery with famotidine in unadjusted results. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
Famotidine in COVID-19 treatment |
Taşdemir et al., Konuralp Tıp Dergisi, doi:10.18521/ktd.935888 |
Retrospective 179 hospitalized patients in Turkey, 85 treated with famotidine and 94 treated with pantoprazole, showing faster recovery with famotidine in unadjusted results.
risk of death, 44.7% lower, RR 0.55, p = 0.29, treatment 5 of 85 (5.9%), control 10 of 94 (10.6%), NNT 21.
|
risk of ICU admission, 36.8% lower, RR 0.63, p = 0.36, treatment 8 of 85 (9.4%), control 14 of 94 (14.9%), NNT 18.
|
hospitalization time, 18.1% lower, relative time 0.82, p = 0.003, treatment 85, control 94.
|
recovery time, 20.0% lower, relative time 0.80, p = 0.04, treatment 85, control 94, duration of fever.
|
Excluded in after exclusion results of meta analysis:
excessive unadjusted differences between groups.
Taşdemir et al., 7/12/2021, retrospective, Turkey, Europe, peer-reviewed, 7 authors, this trial compares with another treatment - results may be better when compared to placebo.
|
Submit Corrections or Comments
|
|
Late |
Elhadi et al., PLOS ONE, doi:10.1371/journal.pone.0251085 |
death, ↓7.1%, p=0.57 |
Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multi-center cohort study |
Details
Prospective study of 465 COVID-19 ICU patients in Libya showing no significant differences with treatment. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multi-center cohort study |
Elhadi et al., PLOS ONE, doi:10.1371/journal.pone.0251085 |
Prospective study of 465 COVID-19 ICU patients in Libya showing no significant differences with treatment.
risk of death, 7.1% lower, RR 0.93, p = 0.57, treatment 34 of 60 (56.7%), control 247 of 405 (61.0%), NNT 23.
|
Excluded in after exclusion results of meta analysis:
unadjusted results with no group details.
Elhadi et al., 4/30/2021, prospective, Libya, Africa, peer-reviewed, 21 authors, study period 29 May, 2020 - 30 December, 2020.
|
Submit Corrections or Comments
|
|
PrEPPEP |
Cheung et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.098 |
severe case, ↑34.0%, p=0.72 |
Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study |
Details
Retrospective 952 COVID-19 patients in Hong Kong, showing no significant difference in severe disease with famotidine use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study |
Cheung et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.098 |
Retrospective 952 COVID-19 patients in Hong Kong, showing no significant difference in severe disease with famotidine use.
risk of severe case, 34.0% higher, OR 1.34, p = 0.72, treatment 23, control 929, adjusted, multivariable, RR approximated with OR.
|
Cheung et al., 4/30/2021, retrospective, China, Asia, peer-reviewed, 3 authors.
|
Submit Corrections or Comments
|
|
Late |
Samimagham et al., Research Square, doi:10.21203/rs.3.rs-462937/v1 (Preprint) |
hosp. time, ↓33.3%, p=0.04 |
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial |
Details
Very small RCT with 20 patients in Iran, showing shorter hospitalization time with famotidine treatment. There was no mortality or ICU admission. Famotidine 160mg four times a day. IRCT20200509047364N2. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial |
Samimagham et al., Research Square, doi:10.21203/rs.3.rs-462937/v1 (Preprint) |
Very small RCT with 20 patients in Iran, showing shorter hospitalization time with famotidine treatment. There was no mortality or ICU admission. Famotidine 160mg four times a day. IRCT20200509047364N2.
hospitalization time, 33.3% lower, relative time 0.67, p = 0.04, treatment 10, control 10.
|
risk of no recovery, no change, RR 1.00, p = 1.00, treatment 5 of 10 (50.0%), control 5 of 10 (50.0%), >50% CT lung involvment.
|
risk of no recovery, 50.0% lower, RR 0.50, p = 0.37, treatment 3 of 10 (30.0%), control 6 of 10 (60.0%), NNT 3.3, no improvement in cough.
|
Samimagham et al., 4/27/2021, Single Blind Randomized Controlled Trial, placebo-controlled, Iran, Middle East, preprint, 6 authors.
|
Submit Corrections or Comments
|
|
Late |
Mura et al., Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00689-y (preprint 3/31/2021) |
death, ↓20.9%, p=0.02 |
Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients |
Details
PSM retrospective TriNetX database analysis of 1,379 severe COVID-19 patients requiring respiratory support, showing lower mortality with aspirin (not reaching statistical significance) and famotidine, and improved results from the combin.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients |
Mura et al., Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00689-y (preprint 3/31/2021) |
PSM retrospective TriNetX database analysis of 1,379 severe COVID-19 patients requiring respiratory support, showing lower mortality with aspirin (not reaching statistical significance) and famotidine, and improved results from the combination of both.
risk of death, 20.9% lower, RR 0.79, p = 0.02, treatment 563, control 563, OR converted to RR, famotidine only, control prevalence approximated with treatment prevalence, propensity score matching.
|
risk of death, 37.3% lower, RR 0.63, p = 0.001, treatment 305, control 305, OR converted to RR, famotidine and aspirin, control prevalence approximated with treatment prevalence, propensity score matching.
|
Mura et al., 3/31/2021, retrospective, database analysis, multiple countries, multiple regions, peer-reviewed, 6 authors.
|
Submit Corrections or Comments
|
|
In Vitro |
Loffredo et al., Scientific Reports, doi:10.1038/s41598-021-84782-w (In Vitro) |
In Vitro |
The in-vitro effect of famotidine on SARS-CoV-2 proteases and virus replication |
Details
In Vitro study showing that famotidine does not bind or inhibit 3CLpro and PLpro, and no direct antiviral activity was observed with concentrations up to 200µM in Vero E6 and A549 cells. |
|
Details
Source
PDF
In Vitro
In Vitro
|
The in-vitro effect of famotidine on SARS-CoV-2 proteases and virus replication |
Loffredo et al., Scientific Reports, doi:10.1038/s41598-021-84782-w (In Vitro) |
In Vitro study showing that famotidine does not bind or inhibit 3CLpro and PLpro, and no direct antiviral activity was observed with concentrations up to 200µM in Vero E6 and A549 cells.
Loffredo et al., 3/8/2021, peer-reviewed, 12 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
|
Submit Corrections or Comments
|
|
PrEPPEP |
Yeramaneni et al., Gastroenterology, doi:10.1053/j.gastro.2020.10.011 |
death, ↓51.0%, p=0.22 |
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System |
Details
Retrospective 7,158 hospitalized COVID-19 patients in the USA, showing higher risk or mortality with in-hospital famotidine use and lower risk with pre-existing use, without statistical significance in both cases. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System |
Yeramaneni et al., Gastroenterology, doi:10.1053/j.gastro.2020.10.011 |
Retrospective 7,158 hospitalized COVID-19 patients in the USA, showing higher risk or mortality with in-hospital famotidine use and lower risk with pre-existing use, without statistical significance in both cases.
risk of death, 51.0% lower, OR 0.49, p = 0.22, treatment 351, control 6,807, adjusted, home use, multivariable, RR approximated with OR.
|
risk of death, 59.0% higher, OR 1.59, p = 0.09, treatment 410, control 746, adjusted, hospital use, multivariable, RR approximated with OR, late treatment result.
|
Yeramaneni et al., 2/28/2021, retrospective, USA, North America, peer-reviewed, 6 authors, study period 11 February, 2020 - 8 May, 2020.
|
Submit Corrections or Comments
|
|
PrEPPEP |
Balouch et al., Journal of Voice, doi:10.1016/j.jvoice.2021.01.007 |
symp. case, ↓22.0%, p=0.49 |
Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study |
Details
Survey of 307 patients in the USA, showing no significant difference in COVID-19 cases with famotidine use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study |
Balouch et al., Journal of Voice, doi:10.1016/j.jvoice.2021.01.007 |
Survey of 307 patients in the USA, showing no significant difference in COVID-19 cases with famotidine use.
risk of symptomatic case, 22.0% lower, RR 0.78, p = 0.49, treatment 18 of 80 (22.5%), control 49 of 227 (21.6%), adjusted, OR converted to RR, multivariable.
|
recovery time, 36.9% lower, relative time 0.63, p = 0.32, treatment 80, control 227.
|
Balouch et al., 1/20/2021, retrospective, USA, North America, peer-reviewed, 5 authors.
|
Submit Corrections or Comments
|
|
Late |
Zhou et al., Gut, doi:10.1136/gutjnl-2020-323668 |
severe case, ↑81.0%, p<0.0001 |
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study |
Details
Retrospective 4,445 COVID+ patients in China, showing higher risk of combined death/intubation/ICU with famotidine treatment. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study |
Zhou et al., Gut, doi:10.1136/gutjnl-2020-323668 |
Retrospective 4,445 COVID+ patients in China, showing higher risk of combined death/intubation/ICU with famotidine treatment.
risk of severe case, 81.0% higher, HR 1.81, p < 0.001, treatment 72 of 519 (13.9%), control 198 of 2,595 (7.6%), death/intubation/ICU, propensity score matching, Cox proportional hazards.
|
Zhou et al., 12/4/2020, retrospective, propensity score matching, China, Asia, peer-reviewed, 7 authors, study period 1 January, 2020 - 22 August, 2020.
|
Submit Corrections or Comments
|
|
Late |
Shoaibi et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000001153 (preprint 9/24/2020) |
death, ↑3.0%, p=0.67 |
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients |
Details
Retrospective 1,816 famotidine users and 26,820 non-users hospitalized for COVID-19 in the USA, showing no significant differences with treatment. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients |
Shoaibi et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000001153 (preprint 9/24/2020) |
Retrospective 1,816 famotidine users and 26,820 non-users hospitalized for COVID-19 in the USA, showing no significant differences with treatment.
risk of death, 3.0% higher, RR 1.03, p = 0.67, treatment 1,816, control 26,820.
|
risk of death/ICU, 3.0% higher, RR 1.03, p = 0.62, treatment 1,816, control 26,820.
|
Shoaibi et al., 9/24/2020, retrospective, database analysis, USA, North America, peer-reviewed, 5 authors.
|
Submit Corrections or Comments
|
|
PrEPPEP |
Mather et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832 |
death, ↓61.4%, p=0.004 |
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19 |
Details
PSM retrospective 878 hospitalized patients in the USA, 83 with existing famotidine use, showing significantly lower mortality with treatment. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19 |
Mather et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832 |
PSM retrospective 878 hospitalized patients in the USA, 83 with existing famotidine use, showing significantly lower mortality with treatment.
risk of death, 61.4% lower, HR 0.39, p = 0.004, treatment 83, control 689, propensity score matching, Cox proportional hazards.
|
risk of death/intubation, 50.5% lower, HR 0.49, p = 0.003, treatment 83, control 689, propensity score matching, Cox proportional hazards.
|
Mather et al., 8/26/2020, retrospective, USA, North America, peer-reviewed, 3 authors.
|
Submit Corrections or Comments
|
|
PrEPPEP |
Freedberg et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.053 |
death/int., ↓57.0%, p=0.02 |
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study |
Details
PSM retrospective 1,620 hospitalized patients in the USA, 84 with existing famotidine use, showing lower risk of combined death/intubation with treatment. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study |
Freedberg et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.053 |
PSM retrospective 1,620 hospitalized patients in the USA, 84 with existing famotidine use, showing lower risk of combined death/intubation with treatment.
risk of death/intubation, 57.0% lower, RR 0.43, p = 0.02, treatment 8 of 84 (9.5%), control 332 of 1,536 (21.6%), NNT 8.3, propensity score matching.
|
Freedberg et al., 5/21/2020, retrospective, propensity score matching, USA, North America, peer-reviewed, 15 authors.
|
Submit Corrections or Comments
|